← Leaderboards
Susan L. Baldwin
Colorado State University-Fort Collins
$5,451,001
Attributed
$10,438,576
Total exposure
6
Grants
1
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $2.3M · FY2016–25$2.5M$1.9M$1.3M$625K$0
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$10,438,576 · 6
By mechanism
R01$9,481,501 · 3
R21$954,823 · 2
F32$2,252 · 1
Top collaborators
- Rhea N Coler10 shared
Most similar at Colorado State University-Fort Collins
Same institution · by research overlap
- Dean C Crick$6,993,235
Others in their field
Top investigators on “Vaccine Candidate”
- Lawrence Corey · Fred Hutchinson Cancer Center$483,977,044
- Margaret Juliana McElrath · Fred Hutchinson Cancer Center$427,604,905
- Barton F Haynes · Duke University$290,267,445
- Kiran Datta · Leidos Biomedical Research, Inc.$277,585,346
- Peter B. Gilbert · Fred Hutchinson Cancer Center$195,104,733
- Wafaa M. El-Sadr · Columbia University Health Sciences$186,594,706
Research focus
Vaccine CandidateAdjuvantLeadMouse ModelInnovationTreatment ProtocolsPharmacotherapyDesignPathogenImmune ResponseIn VivoTuberculosisTherapeutic VaccineRelapseResearch Clinical TestingTreatment EfficacyTuberculosis VaccinesMycobacterium TuberculosisMortalityRouteRegimenPrevalenceEfficacy TestingPrevent
Grant awards (13)
Immunotherapeutic approach for the prevention of secondary infection with drug-resistant TB$978,349
R01 · FY2025 · AI
Targeted vaccines against pulmonary NTM infections in vulnerable populations$950,092
R01 · FY2025 · AI
Immunotherapeutic approach for the prevention of secondary infection with drug-resistant TB$978,338
R01 · FY2024 · AI
Immunotherapy to prevent drug-resistant tuberculosis$1,804,739
R01 · FY2020 · AI
Vaccine-based immunotherapy as an adjunct to drug treatment against NTM$449,268
R21 · FY2020 · AI
Immunotherapy to prevent drug-resistant tuberculosis$802,216
R01 · FY2019 · AI
Vaccine-based immunotherapy as an adjunct to drug treatment against NTM$44,381
R21 · FY2019 · AI
Immunotherapy to prevent drug-resistant tuberculosis$1,337,935
R01 · FY2018 · AI
Development of a Chikungunya Vaccine Candidate$285,720
R21 · FY2018 · AI · contact PI
Immunotherapy to prevent drug-resistant tuberculosis$1,314,028
R01 · FY2017 · AI
Development of a Chikungunya Vaccine Candidate$175,454
R21 · FY2017 · AI · contact PI
Immunotherapy to prevent drug-resistant tuberculosis$1,315,804
R01 · FY2016 · AI
IMMUNITY TO HSV-1 INFECTION IN THE NERVOUS SYSTEM$2,252
F32 · FY2000 · NS